CU22979A1 - Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina - Google Patents

Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina

Info

Publication number
CU22979A1
CU22979A1 CU20000287A CU20000287A CU22979A1 CU 22979 A1 CU22979 A1 CU 22979A1 CU 20000287 A CU20000287 A CU 20000287A CU 20000287 A CU20000287 A CU 20000287A CU 22979 A1 CU22979 A1 CU 22979A1
Authority
CU
Cuba
Prior art keywords
receptors
treatment
kinase activity
combination
typosine
Prior art date
Application number
CU20000287A
Other languages
English (en)
Inventor
Delgado Irene Beausoleil
Ramos Tania Crombet
Marinello Gisela Maria Gonzalez
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Ct Nac Biopreparados
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular, Ct Nac Biopreparados filed Critical Centro Inmunologia Molecular
Priority to CU20000287A priority Critical patent/CU22979A1/es
Priority to PE2001001203A priority patent/PE20020695A1/es
Priority to MYPI20015556A priority patent/MY138833A/en
Priority to AT01999388T priority patent/ATE403438T1/de
Priority to DE60135248T priority patent/DE60135248D1/de
Priority to UY27058A priority patent/UY27058A1/es
Priority to EP08161862A priority patent/EP2005996A3/en
Priority to PCT/CU2001/000012 priority patent/WO2002045747A1/es
Priority to EA200300646A priority patent/EA007381B1/ru
Priority to CA2431199A priority patent/CA2431199C/en
Priority to PT01999388T priority patent/PT1350521E/pt
Priority to AU2002221521A priority patent/AU2002221521B2/en
Priority to CNB018216854A priority patent/CN1326566C/zh
Priority to KR10-2003-7007630A priority patent/KR20030064416A/ko
Priority to SI200130873T priority patent/SI1350521T1/sl
Priority to JP2002547530A priority patent/JP2005519023A/ja
Priority to BR0116010-9A priority patent/BR0116010A/pt
Priority to EP01999388A priority patent/EP1350521B1/en
Priority to NZ526284A priority patent/NZ526284A/en
Priority to MXPA03005030A priority patent/MXPA03005030A/es
Priority to HK05105840.6A priority patent/HK1073244B/xx
Priority to ES01999388T priority patent/ES2311036T3/es
Priority to AU2152102A priority patent/AU2152102A/xx
Priority to DK01999388T priority patent/DK1350521T3/da
Priority to ARP010105686A priority patent/AR031641A1/es
Priority to US10/005,341 priority patent/US20020160014A1/en
Priority to ZA200304415A priority patent/ZA200304415B/en
Publication of CU22979A1 publication Critical patent/CU22979A1/es
Priority to US11/407,103 priority patent/US7744871B2/en
Priority to CY20081101242T priority patent/CY1108474T1/el
Priority to JP2010066088A priority patent/JP2010150286A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

la presente invención se relaciona con el campo de la inmunología y más específicamente con la inmunoterapia del cáncer, particularmente con combinaciones inmunoterapéuticas y métodos de tratamiento para impedir el crecimiento de células tumorales y/o eliminar dichas células. Los métodos descritos en la presente invención se basan en el bloqueo de receptores con actividad de proteínas quinasas en residuos de tirosina (RTK) y de ligandos para dichos receptores. Se describen combinaciones inmunoterapéuticas que provocan el bloqueo de receptores RTK y/o sus ligandos, mediante la combinación de inmunoterapia activa y/o pasiva contra los mismos y los procedimientos referidos pueden ser aplicados a pacientes en diferentes estadios clínicos de tumores de origen epitelial que sobre-expresan estos receptores. La combinación de inmunoterapia activa y pasiva puede ser simultánea o secuencial en dependencia de sí el procedimiento terapéutico va a ser utilizado en pacientes con enfermedad avanzada o como terapia adyuvante.
CU20000287A 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina CU22979A1 (es)

Priority Applications (30)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
PE2001001203A PE20020695A1 (es) 2000-12-08 2001-11-29 Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
MYPI20015556A MY138833A (en) 2000-12-08 2001-12-05 Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity
JP2002547530A JP2005519023A (ja) 2000-12-08 2001-12-06 腫瘍の治療のための免疫療法的併用
BR0116010-9A BR0116010A (pt) 2000-12-08 2001-12-06 Kit imunoterapêutico para o tratamento de tumores
UY27058A UY27058A1 (es) 2000-12-08 2001-12-06 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
EP08161862A EP2005996A3 (en) 2000-12-08 2001-12-06 Immunotherapeutic combination for the treatment of tumors
PCT/CU2001/000012 WO2002045747A1 (es) 2000-12-08 2001-12-06 Combinaciones inmunoterapeuticas para el tratamiento de tumores
EA200300646A EA007381B1 (ru) 2000-12-08 2001-12-06 Иммунотерапевтический набор для лечения опухолей
CA2431199A CA2431199C (en) 2000-12-08 2001-12-06 Immunotherapeutic kit for the treatment of tumors
PT01999388T PT1350521E (pt) 2000-12-08 2001-12-06 Combinações imunoterapêuticas para o tratamento de tumores
AU2002221521A AU2002221521B2 (en) 2000-12-08 2001-12-06 Immunotherapeutic combinations for the treatment of tumors
CNB018216854A CN1326566C (zh) 2000-12-08 2001-12-06 用于治疗肿瘤的免疫治疗药盒
KR10-2003-7007630A KR20030064416A (ko) 2000-12-08 2001-12-06 종양 치료 용 면역치료 조합
SI200130873T SI1350521T1 (sl) 2000-12-08 2001-12-06 Imunoterapevtske kombinacije za zdravljenje tumorjev
AT01999388T ATE403438T1 (de) 2000-12-08 2001-12-06 Immuntherapeutische kombinationen zur tumorbehandlung
DE60135248T DE60135248D1 (de) 2000-12-08 2001-12-06 Immuntherapeutische kombinationen zur tumorbehandlung
EP01999388A EP1350521B1 (en) 2000-12-08 2001-12-06 Immunotherapeutic combinations for the treatment of tumors
NZ526284A NZ526284A (en) 2000-12-08 2001-12-06 mmunotherapeutic combinations comprising antibody/vaccine combinations for the treatment of tumors dependant on tyrosine kinase receptors for growth
MXPA03005030A MXPA03005030A (es) 2000-12-08 2001-12-06 Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.
HK05105840.6A HK1073244B (en) 2000-12-08 2001-12-06 Immunotherapeutic kit for the treatment of tumors
ES01999388T ES2311036T3 (es) 2000-12-08 2001-12-06 Combinaciones de inmunoterapia para el tratamiento de tumores.
AU2152102A AU2152102A (en) 2000-12-08 2001-12-06 Immunotherapeutic combinations for the treatment of tumors
DK01999388T DK1350521T3 (da) 2000-12-08 2001-12-06 Immunoterapeutiske kombinationer til behandling af tumorer
ARP010105686A AR031641A1 (es) 2000-12-08 2001-12-07 Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US10/005,341 US20020160014A1 (en) 2000-12-08 2001-12-07 Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity
ZA200304415A ZA200304415B (en) 2000-12-08 2003-06-05 Immunotherapeutic combinations for the treatment of tumors.
US11/407,103 US7744871B2 (en) 2000-12-08 2006-04-20 Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity
CY20081101242T CY1108474T1 (el) 2000-12-08 2008-11-03 Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων
JP2010066088A JP2010150286A (ja) 2000-12-08 2010-03-23 腫瘍の治療のための免疫療法的併用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina

Publications (1)

Publication Number Publication Date
CU22979A1 true CU22979A1 (es) 2004-09-09

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina

Country Status (25)

Country Link
US (2) US20020160014A1 (es)
EP (2) EP1350521B1 (es)
JP (2) JP2005519023A (es)
KR (1) KR20030064416A (es)
CN (1) CN1326566C (es)
AR (1) AR031641A1 (es)
AT (1) ATE403438T1 (es)
AU (2) AU2152102A (es)
BR (1) BR0116010A (es)
CA (1) CA2431199C (es)
CU (1) CU22979A1 (es)
CY (1) CY1108474T1 (es)
DE (1) DE60135248D1 (es)
DK (1) DK1350521T3 (es)
EA (1) EA007381B1 (es)
ES (1) ES2311036T3 (es)
MX (1) MXPA03005030A (es)
MY (1) MY138833A (es)
NZ (1) NZ526284A (es)
PE (1) PE20020695A1 (es)
PT (1) PT1350521E (es)
SI (1) SI1350521T1 (es)
UY (1) UY27058A1 (es)
WO (1) WO2002045747A1 (es)
ZA (1) ZA200304415B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
CA2665528C (en) * 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
CN102015769B (zh) 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP3583113B1 (en) 2017-02-17 2025-08-20 George Todaro Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ATE188874T1 (de) * 1992-08-18 2000-02-15 Centro Inmunologia Molecular Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69827621T9 (de) * 1997-05-12 2007-06-06 Aphton Corp., Woodland Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
CA2330212A1 (en) * 1998-05-08 1999-11-18 Sloan-Kettering Institute For Cancer Research Compositions and methods for active vaccination
JP2002515511A (ja) * 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6783761B2 (en) * 2000-05-05 2004-08-31 Aphton Corporation Chimeric peptide immunogens
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
EP2005996A3 (en) 2012-01-25
EP1350521B1 (en) 2008-08-06
AR031641A1 (es) 2003-09-24
DE60135248D1 (de) 2008-09-18
CN1592636A (zh) 2005-03-09
CN1326566C (zh) 2007-07-18
US7744871B2 (en) 2010-06-29
JP2010150286A (ja) 2010-07-08
ES2311036T3 (es) 2009-02-01
ATE403438T1 (de) 2008-08-15
NZ526284A (en) 2004-11-26
SI1350521T1 (sl) 2008-12-31
EA007381B1 (ru) 2006-10-27
EA200300646A1 (ru) 2003-10-30
HK1073244A1 (zh) 2005-09-30
WO2002045747A1 (es) 2002-06-13
CA2431199A1 (en) 2002-06-13
BR0116010A (pt) 2004-01-06
DK1350521T3 (da) 2008-11-10
ZA200304415B (en) 2004-07-07
UY27058A1 (es) 2002-03-22
US20020160014A1 (en) 2002-10-31
JP2005519023A (ja) 2005-06-30
AU2152102A (en) 2002-06-18
MXPA03005030A (es) 2004-09-10
US20060188497A1 (en) 2006-08-24
PE20020695A1 (es) 2002-09-23
CA2431199C (en) 2011-10-04
EP1350521A1 (en) 2003-10-08
CY1108474T1 (el) 2014-04-09
KR20030064416A (ko) 2003-07-31
AU2002221521B2 (en) 2007-01-04
MY138833A (en) 2009-07-31
PT1350521E (pt) 2008-11-14
EP2005996A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
CY1108474T1 (el) Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
AR054426A1 (es) Uso de un inhibidor de la dimerizacion de receptores tirosina quinasas her para la manufactura de un medicamento para alargar el tiempo hasta l a progresion de la enfermedad o la supervivencia de los pacientes de cancer
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
MXPA05012723A (es) Tratamiento con anticuerpos anti-vgf.
EA202092154A1 (ru) Комбинированная терапия
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
PE20180131A1 (es) Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cancer
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CU23007A1 (es) Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
EA202190360A1 (ru) Комбинированная терапия
MX2025006565A (es) Terapia contra el cancer con capivasertib y fulvestrant
AR031785A1 (es) Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
NZ760040A (en) Methods of treating brain tumors using combination therapy